Plasma Glucose-Dependent Insulinotropic Polypeptide (GIP)
42-amino-acid incretin peptide secreted by enteroendocrine K-cells in the duodenum and jejunum in response to nutrient absorption.
Standard vs. Optimal Reference Rangespg/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Within standard population reference range, though above optimal longevity targets.
20 - 80 pg/mL (fasting), surges to 200 - 600 pg/mL postprandially
General reference distribution across unselected commercial populations.
Physiological postprandial incretin response
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds GIP receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion, beta-cell survival, and adipose lipid storage.
Differential Diagnosis
Elevated Levels (GIP High)
- •Robust postprandial nutrient absorption
- •Target of dual incretin receptor agonist pharmacotherapy
Low Levels (GIP Low)
- •Impaired incretin effect in late-stage type 2 diabetes
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for GIP
- Targeted organ system imaging or functional dynamic testing related to incretin axis & beta-cell trophic factor
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Plasma Glucose-Dependent Insulinotropic Polypeptide - The New England Journal of Medicine (2021). PMID: 34190124
- [2]GIP Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35422901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Plasma Glucose-Dependent Insulinotropic Polypeptide (GIP) into overall healthspan optimization.